INFORMATION DISCLOSURE CITATION

Page Tofp3 (Use several sheets if necessary) Atty. Docket No. **11020-55**

Serial No. **09/763,666**

Applicant

Stephen R. Ash

Filing Date

Group

February 23, 2001

U.S. PATENT DOCUMENTS

U.S. PATENT DOCUMENTS							
*Examiner Initial	DOCUMENT NUMBER	DATE	NA	ME	CLASS	SUBCLASS	Filing Date If appropriate
M	4,364,929	12/21/1982	2 Sasmor et	Sasmor et al.		80	
n	4,677,143	06/30/1987	7 Laurin et a	1.	523	122	
n	5,032,615	07/16/1991	Ward et al.	•	514	574	
n	5,665,061	09/09/1997	7 Antwiler		604	4	
n	5,709,993	01/20/1998	Buturovic-	Ponikvar	435	2	
N	5,843,016	12/01/1998	3 Lugnani et	al.	604	21	
	- "						
				··· · · · · · · · · · · · · · · · ·			
						į.	1
		FORI	EIGN PATENT	C DOCUME	ENTS	7.007	2
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Trans Yes ⊂	lation 70
		··· ·	·				< 20 CH
							VE 201
					•		
						3700	
					··. • <u>·</u>		}
						Ws.	
			1		,		
Examiner	- 1 /		Date Con	sidered	5/28/0	•	

5/28/03

*Examiner: initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

t	
`	27077
	1 4 /X / /





INFORMATION DISCLOSURE CITATION

Page 2 of 3 (Use several sheets if necessary Atty. Docket No. Serial No. 11020-55 09/763,666

Applicant

Stephen R. Ash

Filing Date

Group

February 23, 2001

OTHER BURNENTS (Including Author, Title, Date, Pertinent Pages, Etc.) *Examiner Initial Olinger GN, Hottenrott C, Mulder DG, Maloney JV, Miller J, Patterson RW, Sullivan SF, Buckberg GD. Acute clinical hypocalcemic myocardial depression during rapid blood transfusion and postoperative hemodialysis. Journal of Thoracic and Cardiovascular Surgery 72: 503-511, October 1976. Dzik WH, Kirkley SP. Citrate toxicity during massive blood transfusion. Transfusion Medicine Reviews 2:76-94, June 1988. Kelleher SP, Schulman G. Severe metabolic alkalosis complicating regional citrate hemodialysis. Am J Kidney Dis 9: 235-236, March 1987. Lohr JW, Slusher S, Diederich D. Safety of regional citrate hemodialysis in acute renal failure. Am J Kidney Dis 8:104-107, February 1989. Leray-Moragues H, Bose LY, Canaud B. Gentamicin/sodium citrate mixture: a promising antibiotic lock for preventing catheter related infections. Lapeyronie Univerity Hospital, Montpellier, France. Von Brecht JH, Flanigan MJ, Freeman RM, Lim VS. Regional anticoagulation: hemodialysis with hypertonic trisodium citrate. Am J Kidney Dis 8:196-201, September 1986. Purchase L, Gault MH. Hemodialysis with a Permcath kept open with streptokinase and later citrate in a heparin-sensitive patient. Nephron 48:119-120, 1991. Flanigan MJ, Pillsbury L, Sadewasser G, Lim VS. Regional hemodialysis anticoagulation: hypertonic tri-sodium citrate or anticoagulant citrate dextrose-A. Am J Kidney D 27:519-524, April 1996. Sodemann K, Lubrich-Birkner I, Berger O, Baumert J, Feldmer B, Von Hodenberg En Gentamicin/sodium-citrate mixture as antibiotic-lock technique for salvage and prevention catheter-related infections – A four year trial. J Am Soc Nephrol 8:173A, 1997. Examiner Date Considered

*Examiner: initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

•		~ ~			
*#137877					
INFOR	RMA	TION DISCLOSURE	Atty. Docket No.	Serial No.	
		CITATION	11020-55	09/763,666	
	F	Page 3 of 301PE	Applicant		
(Use s	sever	al sheets if necessary)	Stephen R. Ash		
		(AUG 1 7 2001 \$	Filing Date	Group	
	•		February 23, 2001		
	Ω'	THER DOCUMENTS (Inclu	ding Author Title Date	Doutingst Dag	rog Eta)
*Examiner		THER DOCUMENTS (Inclu-	ung Author, Title, Date	, refullent rag	es, Etc.)
Initial					
P		Buturovic J, Ponikvar R, Kan catheters in the interdialytic prandomized study. Artif Organized Study.	period: heparin versus cit		
Sp		Branson PK, McCoy RA, Phi maintaining arterial catheter parch 1993.			
	-				
· -					
					<u>.</u>
					<u> </u>
			- '		AUG OLOG
					G21
		:			W M
					RECEIVED AUG 2 2001 TECHNOLOGY CENTER 3700
					R 3
Examiner ()			Date Considered	2	700

Examiner ()

Date Considered

*Examiner: initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

10200-36:GBC:192558 hder the Paperwork Reduction

PTO/SB/08A (12/01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
po persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known Ubstitute for form 1449A/PTO **Application Number** 09/763,666 INFORMATION DISCLOSURE Filing Date February 23, 2001 STATEMENT BY APPLICANT First Named Inventor Stephen R. Ash Group Art Unit (use as many sheets as necessary) **Examiner Name** Sheet Attornev Docket Number 11020-55

LIA BATENT BAARMENTA							
U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
P		6,166,007	12/26/2000	Sodemann			
1		6,423,050 B1	07/23/2002	Twardowski			
1		6,423,706 B2	07/23/2002	Sodemann			
1		6,451,003 B1	09/17/2002	Prosl et al.			
					RECE		
					RECEIVED DEC 0 9 2002 NOLOGY CENTER R3700		
					DFC		
				ITEM	g_{2002}		
				***LUN	NOLOGYCENE		
					OLIVIER R3700		
					. 00		
	Nome of Potentine or Dagger Columns Lines Where						

	Cite	Foreign Patent Document	Publication Date	Name of Patentee or Application of Cited	Pages, Columns, Lines, Where Relevant Passages or Relevant	T4
Initials*	No.¹	Country Code ² -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY	Document	Figures Appear	
			-			
						\vdash
					··········	\vdash
						\vdash
		707 304 (4.14)				\vdash
						i

		_	
Examiner Signature	Salvar	Date Considered	5/28/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.s. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the emperor must precede the serial number of the patent document. ⁵ Kind of document by the apOpropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.